TargetBeta
TMPRSS6
transmembrane serine protease 6 · also FLJ30744, MT2 · Type II transmembrane serine proteases
3 programs in company-led studies act on TMPRSS6, from 3 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| AG-236rule | Agios Pharmaceuticals | phase 3 | 22 running | – | the studies' text |
| sapablursenrule | Ionis Pharmaceuticals | phase 3 | 41 running | – | NCIt |
| Anti-TMPRSS6 Monoclonal Antibody DISC-3405rule | Disc Medicine | phase 2 | 64 running | – | NCIt |
Conditions their studies are in
- Polycythemia Vera, 3 programs
- beta-Thalassemia, 2 programs
- Anemia, Sickle Cell, 1 program
- Thalassemia, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jun 2027Anti-TMPRSS6 Monoclonal Antibody DISC-3405 · Disc Medicine · phase 2 · NCT07187973
- Sep 2028sapablursen · Ionis Pharmaceuticals · phase 3 · NCT07429266
- Aug 2030AG-236 · Agios Pharmaceuticals · phase 3 · NCT07859423
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.